Daxor Co. (NASDAQ:DXR – Get Free Report) was the target of a significant growth in short interest during the month of November. As of November 30th, there was short interest totalling 14,900 shares, a growth of 144.3% from the November 15th total of 6,100 shares. Approximately 0.7% of the shares of the stock are short sold. Based on an average trading volume of 16,600 shares, the short-interest ratio is currently 0.9 days.
Daxor Price Performance
DXR traded up $0.01 on Wednesday, hitting $8.92. 2,325 shares of the company were exchanged, compared to its average volume of 7,524. The firm has a fifty day simple moving average of $9.06 and a two-hundred day simple moving average of $8.98. Daxor has a 12 month low of $7.16 and a 12 month high of $10.04.
Institutional Inflows and Outflows
An institutional investor recently raised its position in Daxor stock. Keyes Stange & Wooten Wealth Management LLC increased its holdings in Daxor Co. (NASDAQ:DXR – Free Report) by 34.8% in the third quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The firm owned 14,612 shares of the company’s stock after acquiring an additional 3,771 shares during the quarter. Keyes Stange & Wooten Wealth Management LLC owned about 0.30% of Daxor worth $126,000 as of its most recent filing with the Securities & Exchange Commission. Institutional investors and hedge funds own 1.34% of the company’s stock.
Analysts Set New Price Targets
Check Out Our Latest Report on Daxor
About Daxor
Daxor Corporation, a medical device company, provides blood volume measurement technology focused on blood volume testing. The company develops and markets BVA-100 Blood Volume Analyzer, a diagnostic blood test to provide safe, accurate, objective quantification of blood volume status and composition compared to patient-specific norms for used in a broad range of medical and surgical conditions.
Featured Articles
- Five stocks we like better than Daxor
- Trading Stocks: RSI and Why it’s Useful
- The Great CPU Race: AMD and Intel Battle for Dominance
- How to Calculate Inflation Rate
- GameStop Turns a Profit: So What? It’s Still Not Worth Investing
- The How And Why of Investing in Oil Stocks
- C3.ai Stock Surges on Strong Sales Despite Profit Concerns
Receive News & Ratings for Daxor Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Daxor and related companies with MarketBeat.com's FREE daily email newsletter.